SCHEMBL6703600

SCHEMBL6703600

CC(CC=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.47
DAO P14920 1/20 0.46
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR2B P41595 1/20 0.45
ACP3 P15309 2/20 0.44
CES2 O00748 1/20 0.44
EPHX1 P07099 1/20 0.42
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
HSD11B1 P28845 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3232486 0.85 HDAC4 (0.39) L3MBTL1ALDH1A1
SCHEMBL19003599 0.84 PNMT (0.47) PNMTDAOHTR2AHTR2CHTR2B
SCHEMBL9580067 0.82 HDAC4 (0.42) CA1CA2ALDH1A1CYP3A4SMN1; SMN2
SCHEMBL13358903 0.81 PNMT (0.51) PNMTDAOHTR2AHTR2CHTR2B
SCHEMBL9952946 0.81 PNMT (0.47) PNMTDAOHTR2AHTR2CHTR2B
SCHEMBL21176912 0.80 HDAC4 (0.35) PNMTACP3CES2EPHX1ATM
SCHEMBL24779791 0.80 PNMT (0.53) PNMTDAOHTR2AHTR2CHTR2B
SCHEMBL10274869 0.80 PNMT (0.53) PNMTDAOHTR2AHTR2CHTR2B
SCHEMBL28724553 0.80 PDE2A (0.42) ACP3CES2CA1CA2HSD11B1
SCHEMBL28724552 0.80 PDE2A (0.42) ACP3CES2CA1CA2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-01-08 US disclosed
EP-1289957-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2003-03-12 EP disclosed
WO-2001087839-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity CCR5, CCR2, CCR1 PNMT 1119/4885DAO 4409/4885HTR2A 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.